| scholarly article | Q13442814 |
| P2093 | author name string | M. A. Rogawski | |
| P2860 | cites work | Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304 | Q24621743 |
| ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma | Q24651797 | ||
| Limbic Network Synchronization and Temporal Lobe Epilepsy | Q26829366 | ||
| Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist | Q27022395 | ||
| Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core | Q27628494 | ||
| TARP auxiliary subunits switch AMPA receptor antagonists into partial agonists | Q27648934 | ||
| Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity | Q27667622 | ||
| 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists | Q27676408 | ||
| Synaptic plasticity: multiple forms, functions, and mechanisms | Q28242702 | ||
| The neurobiology of antiepileptic drugs | Q28267900 | ||
| Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII) | Q28278051 | ||
| Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists | Q32020572 | ||
| Competitive AMPA receptor antagonists | Q33253052 | ||
| Ca(2+) permeable AMPA receptor induced long-term potentiation requires PI3/MAP kinases but not Ca/CaM-dependent kinase II. | Q33405238 | ||
| Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: the Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives. | Q34068562 | ||
| Mechanism of inhibition of GluA2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives: functional consequences of replacing a 7,8-methylenedioxy with a 7,8-ethylenedioxy moiety | Q34150442 | ||
| Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro | Q48826718 | ||
| Cellular mechanism of neuronal synchronization in epilepsy | Q48944149 | ||
| 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia | Q49105194 | ||
| Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists | Q50508039 | ||
| A venus flytrap mechanism for activation and desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors. | Q50761820 | ||
| Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. | Q51768833 | ||
| The non-NMDA receptor antagonist NBQX does not affect rats performance in the object recognition task. | Q52014707 | ||
| AMPA receptor antagonists, GYKI 52466 and NBQX, do not block the induction of long-term potentiation at therapeutically relevant concentrations. | Q52024740 | ||
| Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 | Q56960260 | ||
| The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy | Q67650018 | ||
| The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice | Q67864155 | ||
| Probenecid pretreatment enhances anticonvulsant action of NBQX in mice | Q68011398 | ||
| Synchronous discharges in the rat entorhinal cortex in vitro: site of initiation and the role of excitatory amino acid receptors | Q68463385 | ||
| How do seizures begin? Clues from hippocampal slices | Q69062464 | ||
| Involvement of non-NMDA receptors in picrotoxin-induced epileptiform activity in the hippocampus | Q69378276 | ||
| Antagonism of spontaneous and evoked bursts by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the CA3 region of the in vitro hippocampus | Q69929245 | ||
| The kainate/quisqualate receptor antagonist, CNQX, blocks the fast component of spontaneous epileptiform activity in organotypic cultures of rat hippocampus | Q69931570 | ||
| YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist | Q70891947 | ||
| Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models | Q72101996 | ||
| New non competitive AMPA antagonists | Q72995294 | ||
| Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks | Q34178907 | ||
| Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. | Q34315838 | ||
| (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. | Q34356576 | ||
| In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. | Q34368594 | ||
| Non-competitive AMPA antagonists of 2,3-benzodiazepine type | Q34595297 | ||
| YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. | Q35025108 | ||
| The expanding social network of ionotropic glutamate receptors: TARPs and other transmembrane auxiliary subunits | Q35058291 | ||
| Ionotropic and metabotropic glutamate receptor structure and pharmacology | Q36054635 | ||
| Regulation of AMPA receptor trafficking and synaptic plasticity. | Q36083970 | ||
| Regulatory mechanisms of AMPA receptors in synaptic plasticity | Q36712947 | ||
| Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death | Q36726811 | ||
| The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. | Q36854587 | ||
| AMPA receptors and synaptic plasticity: a chemist's perspective | Q37676916 | ||
| TARPs differentially decorate AMPA receptors to specify neuropharmacology | Q37706709 | ||
| Memory, plasticity and sleep - A role for calcium permeable AMPA receptors? | Q38003608 | ||
| Excitatory amino acid receptors in the vertebrate central nervous system | Q38316536 | ||
| Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach | Q39991874 | ||
| Molecular analysis of the interaction of the pyrazine derivatives RPR119990 and RPR117824 with human AMPA-type glutamate receptor channels | Q40339267 | ||
| Molecular mechanism of AMPA receptor noncompetitive antagonism | Q40359241 | ||
| Excitatory synaptic interactions between CA3 neurones in the guinea-pig hippocampus | Q41904635 | ||
| Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs | Q42287869 | ||
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside | Q43113304 | ||
| 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist. | Q43911240 | ||
| Functional characterization of YM928, a novel moncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist | Q44378881 | ||
| Expression of transcripts encoding AMPA receptor subunits and associated postsynaptic proteins in the macaque brain | Q44702192 | ||
| Effect of YM928, a novel AMPA receptor antagonist, on seizures in EL mice and kainate-induced seizures in rats | Q45025717 | ||
| Synaptic and intrinsic conductances shape picrotoxin-induced synchronized after-discharges in the guinea-pig hippocampal slice | Q46177192 | ||
| Inhibitory control of local excitatory circuits in the guinea-pig hippocampus | Q46539366 | ||
| Stargazin modulates AMPA receptor antagonism | Q46672870 | ||
| Single neurones can initiate synchronized population discharge in the hippocampus | Q46865979 | ||
| Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy | Q46887470 | ||
| Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. | Q47880985 | ||
| New quinoxalinediones show potent antagonism of quisqualate responses in cultured mouse cortical neurons | Q48087676 | ||
| Effects of YM90K, a selective AMPA receptor antagonist, on amygdala-kindling and long-term hippocampal potentiation in the rat. | Q48152058 | ||
| Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy | Q48171460 | ||
| The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures | Q48178824 | ||
| SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity | Q48205226 | ||
| Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. | Q48278700 | ||
| Electrophysiological substrates for focal epilepsies | Q48291431 | ||
| GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses | Q48392369 | ||
| NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil | Q48470338 | ||
| Low-calcium field burst discharges of CA1 pyramidal neurones in rat hippocampal slices | Q48627089 | ||
| The involvement of excitatory amino acids in neocortical epileptogenesis: NMDA and non-NMDA receptors | Q48824426 | ||
| P433 | issue | 197 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 9-18 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Acta neurologica Scandinavica. Supplementum | Q27020379 |
| P1476 | title | AMPA receptors as a molecular target in epilepsy therapy |
| Q41917625 | A combination of NMDA and AMPA receptor antagonists retards granule cell dispersion and epileptogenesis in a model of acquired epilepsy |
| Q36202511 | AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets |
| Q38134724 | Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy? |
| Q36575895 | BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice |
| Q38154633 | BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy |
| Q51749309 | Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population. |
| Q55300091 | Complete Resolution of Symptoms of Primary Orthostatic Tremor with Perampanel. |
| Q90004768 | Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: A Spanish perspective |
| Q46748196 | Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish. |
| Q38675314 | Current role of perampanel in pediatric epilepsy. |
| Q38088290 | Development of perampanel in epilepsy |
| Q57788206 | Differential modulation of NMDA and AMPA receptors by cellular prion protein and copper ions |
| Q36174777 | EGAR, A Food Protein-Derived Tetrapeptide, Reduces Seizure Activity in Pentylenetetrazole-Induced Epilepsy Models Through α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionate Receptors |
| Q37571770 | Early-life stress impacts the developing hippocampus and primes seizure occurrence: cellular, molecular, and epigenetic mechanisms |
| Q90390690 | Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics |
| Q30728243 | Efficacy of perampanel: a review of pooled data |
| Q27715636 | Elucidation of AMPA receptor-stargazin complexes by cryo-electron microscopy |
| Q36284015 | Epilepsy-associated gene Nedd4-2 mediates neuronal activity and seizure susceptibility through AMPA receptors. |
| Q30008868 | Expression of SHANK3 in the Temporal Neocortex of Patients with Intractable Temporal Epilepsy and Epilepsy Rat Models |
| Q66679720 | Functional Nutrients for Epilepsy |
| Q34233508 | Ganglioside regulation of AMPA receptor trafficking |
| Q41792375 | GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile |
| Q34048502 | Glutamate as a neurotransmitter in the healthy brain |
| Q38535033 | Glutamatergic Mechanisms Associated with Seizures and Epilepsy |
| Q39011258 | Guanosine protects C6 astroglial cells against azide-induced oxidative damage: a putative role of heme oxygenase 1. |
| Q59795983 | High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology |
| Q88687361 | Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability |
| Q90520789 | Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors |
| Q39120013 | Lens Biology is a Dimension of Neurobiology |
| Q57970623 | Leptin: role over central nervous system in epilepsy |
| Q28272457 | Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet |
| Q47771228 | Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. |
| Q92490611 | Modulation of AMPA Receptor Gating by the Anticonvulsant Drug, Perampanel |
| Q47601255 | On Rhythms in Neuronal Networks with Recurrent Excitation |
| Q64076569 | Perampanel Affects Up-Stream Regulatory Signaling Pathways of GluA1 Phosphorylation in Normal and Epileptic Rats |
| Q57175088 | Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus |
| Q26796447 | Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability |
| Q21131943 | Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons |
| Q30819017 | Physiological bases of the K+ and the glutamate/GABA hypotheses of epilepsy |
| Q30837245 | Precision therapy for a new disorder of AMPA receptor recycling due to mutations in ATAD1. |
| Q27022395 | Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist |
| Q35117565 | Reactive astrogliosis causes the development of spontaneous seizures |
| Q47112846 | Regulation of AMPA Receptor Trafficking by Protein Ubiquitination. |
| Q90481628 | Regulation of Ion Channels by MicroRNAs and the Implication for Epilepsy |
| Q64274255 | Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management |
| Q41598077 | Structural Bases of Desensitization in AMPA Receptor-Auxiliary Subunit Complexes |
| Q92628295 | Successful Treatment of Primary Orthostatic Tremor Using Perampanel |
| Q40016074 | Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy |
| Q34395565 | Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. |
| Q38205934 | The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy |
| Q36909520 | The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications |
| Q37559828 | The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. |
| Q27349241 | Transferrin Receptor Controls AMPA Receptor Trafficking Efficiency and Synaptic Plasticity |
| Q36097600 | Volterra representation enables modeling of complex synaptic nonlinear dynamics in large-scale simulations. |
| Q34679478 | X-ray structures of AMPA receptor-cone snail toxin complexes illuminate activation mechanism |
| Q59356159 | ZDHHC8 critically regulates seizure susceptibility in epilepsy |
Search more.